Sign in →

Test Code GAL3 Galectin-3, Serum

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Useful For

An aid in prognosis for patients diagnosed with heart failure

 

Risk-stratification of heart failure patients

 

An early indication of treatment failure and as a therapeutic target

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

Galectin-3, S

Specimen Type

Serum Red


Specimen Required


Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL


Specimen Minimum Volume

0.2 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Frozen (preferred) 365 days
  Refrigerated  24 hours

Reject Due To

Hemolysis

Mild reject; Gross reject

Lipemia

Mild OK; Gross reject

Icterus

NA

Other

NA

Reference Values

<24 months: not established

2-17 years: ≤25.0 ng/mL

≥18 years: ≤22.1 ng/mL

Interpretation

Clinically, galectin-3 concentrations may be categorized into 3 risk categories, substantiated by results from several large chronic heart failure studies:(2-4)

≤17.8 ng/mL (low risk)

17.9-25.9 ng/mL (intermediate risk)

>25.9 ng/mL (higher risk)

 

Results should be interpreted in the context of the individual patient presentation. Elevated galectin-3 results indicate an increased risk for adverse outcomes and signal the presence of galectin-3-mediated fibrosis and adverse remodeling. Once galectin-3 concentrations are elevated they are relatively stable over time in the absence of intervention.

 

Knowledge of a heart failure patient's galectin-3 results may assist in risk stratification and lead to more aggressive management. There are no specific galectin-3 inhibitors available at this time and heart failure patients with elevated galectin-3 concentrations should be treated and monitored according to established guidelines. Angiotensin receptor blockers (ARBs) and aldosterone antagonists are thought to be particularly effective. 

 

A large multicenter, prospective, observational study was conducted to derive the reference intervals for galectin-3 that included 1,092 subjects between the ages of 55 and 80 years without any known cardiac disease (520 males, 572 females).(5) The 97.5th percentile of galectin-3 in that cohort was 22.1 ng/mL. Individuals with concentrations >22.1 ng/mL had a significant association with mortality and New York Heart Association (NYHA) classification. However, this was an older population and definitive evidence of cardiac disease was not documented. 

Day(s) and Time(s) Performed

Monday; 9 a.m.

Analytic Time

1 day

Specimen Retention Time

14 Days

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

82777-Galectin-3

LOINC Code Information

Test ID Test Order Name Order LOINC Value
GAL3 Galectin-3, S 62419-7

 

Result ID Test Result Name Result LOINC Value
86202 Galectin-3, S 62419-7

Forms

If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.